Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Corbus Pharma raises US$27mln to advance fibrosis drug

Friday, March 3, 2017 7:46
% of readers think this story is Fact. Add your two cents.

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) has raised US$27.2mln from investors in a direct offering.

The drug developer sold 3.9mln shares at US$7 each; a 34% discount to Thursday’s market close.

Corbus will use the money to advance its JBT-101 fibrosis treatment, as well as to top up its working capital.

 “We are pleased with the outcome of this financing which should fund the company through several important milestones across all of our four clinical programs,” said chief executive Yuval Cohen.

The company is now sitting on a cash pile of US$39.4mln which it reckons should see it through until the fourth quarter of 2018 based on current planned expenditure.

As well as JBT-101, Corbus has a couple of other candidates in clinical trials at the moment; a dermatomyositis treatment and a lupus candidate.

Shares opened higher at US$9.40 on Friday morning.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.